Top Markets
#1 Black Phoenix Black Phoenix +354.04%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +69.28%
#4 Gold Park Gold Park +58.04%
#5 Acurast Acurast +39.30%
#6 OpenEden OpenEden +35.14%
#7 BasedHype BasedHype +27.14%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.38%
#9 Cryptopia Cryptopia +21.54%
#10 Avantis Avantis +17.76%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
TFF Pharmaceuticals, Inc. TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals, Inc.

TFFP
Kedudukan dalam Saham #40711
Operating as a clinical-stage biopharmaceutical company, TFF Pharmaceuticals,... Operating as a clinical-stage biopharmaceutical company, TFF Pharmaceuticals, Inc., leverages its proprietary Thin Film Freezing (TFF) technology platform for the advancement and commercialization of therapeutic products across the United States and Australia. A primary emphasis is placed on creating inhaled dry powder formulations to address various pulmonary ailments and disorders. Its two leading drug candidates, both currently in Phase II clinical trials, include TFF Voriconazole Inhalation Powder, designed to combat invasive pulmonary aspergillosis, and TFF Tacrolimus Inhalation Powder, aimed at preventing lung transplant rejection. Beyond these, the company's pipeline features other dry powder products like a cannabidiol substance targeting various epilepsy syndromes, anxiety, insomnia, and pain; an Inhaled SARS-CoV2 Monoclonal Antibody for COVID-19 patients; Niclosamide Inhalation Powder, intended for human tapeworm infections and COVID-19; and a range of other vaccines. Strategic partnerships are also central to its operations, including a licensing arrangement with the University of Texas at Austin for inhaled dry powder drug development, a joint development pact with Augmenta Bioworks, Inc. for the inhaled SARS-CoV2 monoclonal antibody, and a broad licensing and collaboration agreement with UNION therapeutics A/S. Established in 2018, the company maintains its headquarters in Austin, Texas.
Harga Saham
$0.065
Disegerakkan terakhir: 2025-01-10
Modal Pasaran
$94.10K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan TFF Pharmaceuticals, Inc. (TFFP)

Kategori

Healthcare
Nisbah P/E bagi TFF Pharmaceuticals, Inc. (TFFP)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini TFF Pharmaceuticals, Inc., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi TFF Pharmaceuticals, Inc. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.